28,461 Shares in MBX Biosciences, Inc. $MBX Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in MBX Biosciences, Inc. (NASDAQ:MBX) in the 3rd quarter, HoldingsChannel reports. The fund purchased 28,461 shares of the company’s stock, valued at approximately $498,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Virtus Investment Advisers LLC increased its position in MBX Biosciences by 9.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 8,772 shares of the company’s stock valued at $100,000 after buying an additional 766 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MBX Biosciences by 40.3% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock worth $106,000 after purchasing an additional 2,682 shares in the last quarter. XTX Topco Ltd bought a new position in shares of MBX Biosciences in the second quarter valued at $135,000. Intech Investment Management LLC lifted its position in MBX Biosciences by 33.0% in the 2nd quarter. Intech Investment Management LLC now owns 14,271 shares of the company’s stock valued at $163,000 after acquiring an additional 3,543 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in MBX Biosciences by 171.6% during the 2nd quarter. Rhumbline Advisers now owns 23,662 shares of the company’s stock valued at $270,000 after purchasing an additional 14,950 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group started coverage on MBX Biosciences in a report on Thursday, December 4th. They issued a “sell” rating and a $18.00 target price on the stock. Wall Street Zen raised MBX Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. Truist Financial started coverage on shares of MBX Biosciences in a report on Wednesday, October 15th. They issued a “buy” rating and a $50.00 target price for the company. Barclays initiated coverage on MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 target price for the company. Finally, TD Cowen assumed coverage on shares of MBX Biosciences in a report on Tuesday, November 4th. They issued a “buy” rating on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.20.

MBX Biosciences Price Performance

Shares of MBX opened at $39.07 on Tuesday. The business’s 50-day moving average is $33.61. MBX Biosciences, Inc. has a 52-week low of $4.81 and a 52-week high of $44.89. The stock has a market cap of $1.75 billion, a PE ratio of -16.35 and a beta of 0.87.

MBX Biosciences (NASDAQ:MBX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.10.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.